Abstract: A thermoplastic resin finely-foamed reflective sheet, containing: a foamed layer; and non-foamed layers, each of which has a thickness of 150 ?m or less and 30 ?m or more, and which are provided one above the other while sandwiching the foamed layer between the non-foamed layers, wherein the thermoplastic resin finely-foamed reflective sheet has an integrated structure, wherein the foamed layer is a thermoplastic resin finely-foamed product having a homogeneous bubble structure, in which an average bubble diameter is 10 ?m or less and 0.5 ?m or more, and in which a bubble number density is 1×106/mm3 or more and 1.0×1012/mm3 or less, and wherein at least one of the non-foamed layers comprises a functionality-providing layer.

Abstract: The invention provides a ferritic heat-resistant steel whose creep rupture ductility in a long-term region is improved without detrimental to creep strengths. The ferritic heat-resistant steel has a chemical composition comprising, in % by mass, C: 0.03 to 0.15, Si: 0 to 0.8, Mn: 0.1 to 0.8, Cr: 8.0 to 11.5, Mo: 0.2 to 1.5, (W: 0.4 to 3.0), V: 0.1 to 0.4, Nb: 0.02 to 0.12 N: 0.02 to 0.10 with the balance of iron and inevitable impurities. This steel has a tempered martensite microstructure, and has an improved creep rupture ductility even when there is a load within the elastic limits at temperatures at which the ferritic heat-resistant steel is used, because internal strain or internal stress induced by martensitic transformation is relaxed or released by an intermediate tempering heat treatment in a two-phase state temperature in which a portion of an austenitic phase undergoes martensitic transformation.

Abstract: The present invention addresses the problem of providing a novel therapeutic agent for keratoconjunctive disorders. As a means for solving the problem, a therapeutic agent for keratoconjunctive disorders which contains a RAR? agonist as an active ingredient is provided. The therapeutic agent exhibits an excellent ameliorating effect in a keratoconjunctive disorder model, and is therefore useful as a therapeutic agent for keratoconjunctive disorders such as corneal ulcer, corneal epithelial abrasion, keratitis, dry eye, conjunctivitis, chronic superficial keratitis, corneal erosion, persistent corneal disorders, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, infectious keratitis, noninfectious keratitis, infectious conjunctivitis and noninfectious conjunctivitis.

Abstract: [Solution] Provided is a water purification agent suitable for use in an automated purification treatment device, when a wastewater purification treatment using a plant-derived water purification agent is performed with the automated purification treatment device. The water purification agent is a granulated product containing a mixture of a plant powder and a polymer coagulant.

Abstract: The present invention addresses the problem of providing a novel therapeutic agent for keratoconjunctive disorders. As a means for solving the problem, a therapeutic agent for keratoconjunctive disorders which contains a RAR? agonist as an active ingredient is provided. The therapeutic agent exhibits an excellent ameliorating effect in a keratoconjunctive disorder model, and is therefore useful as a therapeutic agent for keratoconjunctive disorders such as corneal ulcer, corneal epithelial abrasion, keratitis, dry eye, conjunctivitis, chronic superficial keratitis, corneal erosion, persistent corneal disorders, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, infectious keratitis, noninfectious keratitis, infectious conjunctivitis and noninfectious conjunctivitis.

Abstract: Disclosed is a power transmission apparatus that is cooled by airflow sent from a fan and includes fins provided on side surfaces of a casing. The fins include upstream fins close to the fan and downstream fins distant from the fan. An interval between the upstream fins is smaller than an interval between the downstream fins.

Abstract: [Solution] Provided is a plant-derived water purifying agent used for water purification for industrial wastewater, etc. and including a granulated product of a plant powder, such that when a wastewater purifying treatment using the plant-derived water purifying agent is performed by an automated purifying treatment device, the water purifying agent can be suitably used in the automated purifying treatment device. It is more preferable that a Carr's fluidity index of the water purifying agent obtained by measuring 3 items of the water purifying agent, which are an angle of repose, a degree of compression, and a spatula angle be 40 or greater.

Abstract: A heating part of covering and heating a gas pipe includes: a thermal insulation portion disposed outside a heat generation body; an enclosure configured to enclose the thermal insulation portion and the heat generation body; a fastening part installed outside the enclose and configured to fasten one end portion and the other end portion of the enclosure in a state in which the one end portion and the other end portion of the enclosure adjoin each other; and a temperature sensing part disposed at the side of the gas pipe with respect to the enclosure at a position facing a surface of the gas pipe and formed in a plate shape with a major surface thereof oriented toward the gas pipe.

Abstract: The present invention addresses the problem of providing a novel therapeutic agent for keratoconjunctive disorders. As a means for solving the problem, a therapeutic agent for keratoconjunctive disorders which contains a RAR? agonist as an active ingredient is provided. The therapeutic agent exhibits an excellent ameliorating effect in a keratoconjunctive disorder model, and is therefore useful as a therapeutic agent for keratoconjunctive disorders such as corneal ulcer, corneal epithelial abrasion, keratitis, dry eye, conjunctivitis, chronic superficial keratitis, corneal erosion, persistent corneal disorders, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, infectious keratitis, noninfectious keratitis, infectious conjunctivitis and noninfectious conjunctivitis.

Abstract: An object of the present invention is to provide a method which enable a material to be fully embedded into a recess portion with a deposition film left in the recess portion. A method in one embodiment comprises: a first irradiation step of irradiating a deposition film formed on an opening portion of a recess portion in a substrate with a particle beam in a direction at a first angle with respect to a substrate in-plane direction, to remove part of the deposition film in a thickness direction; and a second irradiation step of, after the first irradiation step, irradiating the deposition film with the particle beam in a direction at a second angle which is closer to perpendicular to the substrate in-plane direction than the first angle is, to remove part of the remaining deposition film in the thickness direction.

Abstract: The present invention addresses the problem of providing a novel therapeutic agent for keratoconjunctive disorders. As a means for solving the problem, a therapeutic agent for keratoconjunctive disorders which contains a RAR? agonist as an active ingredient is provided. The therapeutic agent exhibits an excellent ameliorating effect in a keratoconjunctive disorder model, and is therefore useful as a therapeutic agent for keratoconjunctive disorders such as corneal ulcer, corneal epithelial abrasion, keratitis, dry eye, conjunctivitis, chronic superficial keratitis, corneal erosion, persistent corneal disorders, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, infectious keratitis, noninfectious keratitis, infectious conjunctivitis and noninfectious conjunctivitis.

Abstract: Disclosed is a speed reduction apparatus including: a casing that accommodates a speed reduction mechanism; an input shaft including a protruding portion protruding from the casing to the outside; a fan provided on the protruding portion of the input shaft; and a fan hood that covers the fan. The fan hood includes a cylindrical portion, and a trumpet-like portion that is connected to the cylindrical portion, and includes an inner surface inclined to be separated away from the input shaft toward a load side. A flow straightening fin is provided on an inner surface of the trumpet-like portion.

Abstract: An object of the present invention is to provide a method which enable a material to be fully embedded into a recess portion with a deposition film left in the recess portion. A method in one embodiment comprises: a first irradiation step of irradiating a deposition film formed on an opening portion of a recess portion in a substrate with a particle beam in a direction at a first angle with respect to a substrate in-plane direction, to remove part of the deposition film in a thickness direction; and a second irradiation step of, after the first irradiation step, irradiating the deposition film with the particle beam in a direction at a second angle which is closer to perpendicular to the substrate in-plane direction than the first angle is, to remove part of the remaining deposition film in the thickness direction.

Abstract: The present invention addresses the problem of providing an inhibitor for retinochoroidal disorders, in particular, an inhibitor for retinochoroidal scar formation and retinochoroidal atrophy in an epiretinal, intraretinal or subretinal tissue. This problem can be solved by preparing an inhibitor for retinochoroidal disorders which comprises, as an active ingredient, (E)-4-(2-{3-[(1H-pyrazol-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid, an ester thereof or a salt of the same. The inhibitor for retinochoroidal disorders can inhibit collagen atrophy of retinal pigment epithelium cells, fibroblasts, glial cells and the like and thus inhibit retinochoroidal disorders.

Abstract: Disclosed is a power transmission apparatus that is cooled by airflow sent from a fan and includes fins provided on side surfaces of a casing. The fins include upstream fins close to the fan and downstream fins distant from the fan. An interval between the upstream fins is smaller than an interval between the downstream fins.

Abstract: The present invention addresses the problem of providing a novel therapeutic agent for keratoconjunctive disorders. As a means for solving the problem, a therapeutic agent for keratoconjunctive disorders which contains a RAR? agonist as an active ingredient is provided. The therapeutic agent exhibits an excellent ameliorating effect in a keratoconjunctive disorder model, and is therefore useful as a therapeutic agent for keratoconjunctive disorders such as corneal ulcer, corneal epithelial abrasion, keratitis, dry eye, conjunctivitis, chronic superficial keratitis, corneal erosion, persistent corneal disorders, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, infectious keratitis, noninfectious keratitis, infectious conjunctivitis and noninfectious conjunctivitis.

Abstract: In a method for manufacturing the functional element, a protective film covering an underlayer, a patterned multilayer film, and a patterned cap layer are formed, and the underlayer is then processed without newly forming a resist. Thereby, an electrode can be formed in steps less than ever before. Since the protective film formed on the patterned multilayer film and the patterned cap layer is used as a mask, the problem of the misregistration can be prevented.

Abstract: By focusing on the fact that nitrogen dioxide exhibits an increased sterilizing effect among other sterilant gases including nitrogen oxide, the present invention is made to provide a sterilization method which may be suitably used for sterilizing items to be sterilized such as medical instruments which require increased reliability by using a high concentration NO2 gas of 5,000 ppm or above, for example. An inside of a sterilizing chamber containing an item to be sterilized is humidified, and a concentration of NO2 in the sterilizing chamber is made to be from 9 to 100 mg/L by filling a high concentration NO2 gas.

Abstract: A thermoplastic resin finely-foamed reflective sheet, containing: a foamed layer; and non-foamed layers, each of which has a thickness of 150 ?m or less and 30 ?m or more, and which are provided one above the other while sandwiching the foamed layer between the non-foamed layers, wherein the thermoplastic resin finely-foamed reflective sheet has an integrated structure, wherein the foamed layer is a thermoplastic resin finely-foamed product having a homogeneous bubble structure, in which an average bubble diameter is 10 ?m or less and 0.5 ?m or more, and in which a bubble number density is 1×106/mm3 or more and 1.0×1012/mm3 or less, and wherein at least one of the non-foamed layers comprises a functionality-providing layer.

Abstract: In a method for manufacturing the functional element, a protective film covering an underlayer, a patterned multilayer film, and a patterned cap layer are formed, and the underlayer is then processed without newly forming a resist. Thereby, an electrode can be formed in steps less than ever before. Since the protective film formed on the patterned multilayer film and the patterned cap layer is used as a mask, the problem of the misregistration can be prevented.